English (United States)|Italiano (Italia)
English (United States) | Italiano (Italia)
The group

The internationalization process and establishment of all Group companies

1982 Italfarmaco's first product "Selezen" (imidazate) is marketed.
1983 Acquisition of the majority of LPB shares and requalification of the research laboratories at the LPB office in Cinisello Balsamo with relocation of the research staff.
1984 Acquisition of CHEMI Spa by Italfarmaco (Chemi becomes a subsidiary company involved in the production and marketing of semi finished and finished chemical products). Founded in 1973, the new plant in Patrica (FR) is inaugurated in 1974.
1986 Market launch of Nicardal 20 (arterial hypertension).
1988 Market launch of Ferplex (Ferrous protein succinylate) manufactured by Italfarmaco Research laboratory.
1989 Market launch of Gliatilin, manufactured by Italfarmaco research laboratory (choline alfoscerate).
1990 Italfarmaco is awarded with the U.N.A.M.S.I. prize (Unione Nazionale Medici Collaboratori della Stampa di informazione italiana) "Carlo Guidetti" for researchers and representatives of praiseworthy companies in medical scientific communication.
Inauguration of the production installation of alpha-Glycerophosphorylcholine in the Chemi manufacturing plant in Patrica (FR).
1991 Foundation of Italfarmaco SA Spain (Madrid): with a production plant which manufactures oral liquids and focuses on the respiratory therapeutic, cardiovascular and gynecological areas).

CHEMI opens a waste water treatment plant (with high technological quality and importance for environmental protection of the site).
1993 Italfarmaco obtains acknowledgement for national funding of several research projects.
1994 The research development of Italfarmaco goes on. The research results of ILOPROST (prostanoide) and CALCIPARINA (antithrombotic) anticoagulants for preventive treatment of severe peripheral arterial diseases are published.
1995 Foundation of Italfarmaco Holding Spa. Francesco De Santis is appointed to the position of President.

Introduction of one of the company's top product, "Myelostim" (lenograstim: Granulocyte-Colony Stimulating Factor G-CSF growth factors), thanks to the partnership with the Japanese firm Chugai. In 2009 Italfarmaco markets Granocyte, manufactured by Chugai.
1996 Foundation of the Laboratorios Farmacèutico Logogen Sa (Spain) - second commercial line of Italfarmaco SA Spain.
1997 Acquisition of Lifepharma – (Milan: acquisition) - sale of generic drugs mainly targeting foreign markets such as the Middle East and North Africa.

Italfarmaco Spa transfers its commercial offices and administrative branch to Cinisello Balsamo. The Milan manufacturing plant, located at 330 Viale Fulvio Testi, is focused on Italian production lines and logistic facilities.

In that same year, Italfarmaco SA Spain establishes its third commercial line: Laboratorios Farmacéutico Valomed SA (Spain).
1998 Foundation of ITF Farma Chile SA in Santiago, which deals completely with commercial activities
1999 Opening of a representative office in Russia (located in Moscow. Start-up operations in Georgia and Azerbaijan).

Foundation of ITF Farma Produtos Farmacêutico Lda Portuguese branch office of Italfarmaco S.A. based in Barcarena-Lisbon. The office deals completely with commercial activities.
2000 ITF Chemical Ltda, Brazil (chemical production located at Camacari/S. de Bahia) and opening ceremony of the plant in 2001.
2001 A new company in the group is founded: Chemi Nutraeuticals, USA.

Foundation of Italfarmaco Hellas, in Athens which markets gynaecologic and neurologic products.

Italfarmaco launches the chemotherapy product MUPHORAN® (fotemustine).
2002 Foundation of ITF Medigen Produtos Farmacêutico Lda (Portugal): a commercial line linked with Italfarmaco SA.
2003 Acquisition of shares from the participated company EffikFrance (Effik group, active in Italy, Portugal and Spain (and then in Switzerland) which is specialized in the gynecological field, with contraceptive products, hormonal replacement treatments for menopause, sterility and acne).
2004 Foundation of Laboratorios Farmacéuticos Medilab SA (Spain) – a company which performs medical diagnostic activities.

Italfarmaco Milan gets the FDA Certification for the manufacturing of sterilized pre-filled syringes.

Foundation of CHEMI LLC.
2005 Italfarmaco completes the acquisition of ITF Farma Chile SA.

Italfarmaco Italia launches Vasexten (barnidipine) an antihypertensive agent.
2006 Foundation of ITF-Medical Produtos Famacêuticos Lda (Portugal) – which incorporates two commercial lines from ITF Portugal.

Italfarmaco launches Aloxi (Palonosetron) an antiemetic for chemotherapy.
2007 Inauguration of Italfarmaco Spa new Gynecological Business Unit (which joins the immunocologic and vascular line already active in the company).

FDA confirms certification for the manufacturing plant. Focus inspection: sterilized pre-filled syringes for Epinefrine.

The prize for Best sales Growth at the Aloxi Awards is conferred to Italfarmaco.
2008 The first data concerning the use/development of a new conditioning scheme of the peripheral stem cell transplant with fotemustine (an alkylating agent) are registered. The previous regimen for marrow pre-transplant was implemented by a "beam" scheme (with the use of carmustine an alkylating agent), but now the "feam" regimen using fotemustine is employed.
2009 Acquisition of Instituto Farmacéutico Labomed SA (located in Santiago, it deals with commercial and productive activities) and merger with ITF Farma Chile SA in ITF-Labomed Farmaceutica Limitada.

In the same year, the Turkey representative office opens: ITF ILAÇ.
2010 Versalya SA (Morocco) is founded.

Italfarmaco Italia in 2009 and 2010 (with Pletal, Zarelis and Saforelle) markets the largest number of products (Natecal Oro, Fentalgon, Treoject, Natalben più, Inofert).

FDA certification renewal for the production plant Italfarmaco. Focus inspection: sterilized pre-filled syringes for Octreotide and Enoxaparina.

FDA Inspection CHEMI (Cinisello). Focus inspection: pre-filled syringes for Octreotide Acetate.

FDA Inspection CHEMI (Patrica): Focus inspection: Enoxaparina.
2011 Ferplex Fol and Sonirem are launched onto the Italian market.

ANVISA inspection on the Brazilian Italfarmaco premises: successful outcome with GMP certification expected in August.

Italfarmaco SA Spain celebrates its twenty years of operations.
2012 Italfarmaco Group's consolidation in Scandinavian countries.

Italfarmaco Italia markets new products: Gelistrol, Zaredrop, Folifill.
2013 Italfarmaco achieves the Best Poster Critics Choice's Award at the "Aloxi ten years of Marketing celebration" event by Helsinn Healthcare.
28 november - Sevelamer New Plant Inauguration by ITF Chemical (Bahia –Brasil) (Sevelamer is a treatment for the chronic renal impairment).
2014 June - Inauguration of the new Italfarmaco representative office in Moscow.
June - FDA approval for Enoxaparin ANDA by Teva, partner of Chemi (production starts at Italfarmaco’s plant in Milan).
December - Acquisition of Edwards Pharmaceuticals Inc. by our affiliate, Women’s Choice Pharmaceuticals, LLC, in the U.S.
Market launch of Xarenel (cholecalciferol), Coripren (lercanidipine + enalapril), Zenaus (ginger-based supplement), Teglutik (riluzole), Inofert (inositol-based supplement).
2015 July - GMP approval by the Turkish Authorities after the inspection of the production plant Italfarmaco in Milan.
Market Launch of AINARA (carbopol+polycarbophil-based medical device).
September - AOpening of the Italfarmaco Group representative office in Vietnam.
September - The Italfarmaco Group announces the acquisition of the remaining 50% in Effik, S.A.
2016 January - Madrid, Italfarmaco Spain celebrates 25 years. Madrid, Italfarmaco Spain celebrates 25 years
2-3 March - Market launch of Akynzeo, new NK-1 antagonist serotonergic (combination of Palonosetron + netupitant) in fixed-dose oral formulation. De Santis e Barbaglia
Foto gruppo Akynzeo
September - Launch of Flavia: supplement of women in menopause.
September – October - Two launches in the Primary Care of Italfarmaco: Gliatilin with new vials (area of the Central Nervous System) and the Filifill120 tablets with new dosage (Cardiovascular area).
2017 May - Natalben Oro and Natalben Supra launches expand the range of multivitamin and multimineral supplements designed for pregnancy.
2018 June – Athens Greece, ITF Hellas celebrates 20 years. Athens Greece, ITF Hellas celebrates 20 years
September - ITF PHARMA announces FDA approval of TIGLUTIK™ (riluzole) oral suspension for the tratment of amyotrophic lateral sclerosis (ALS).
September - New Marketing launch of SONIDOR, a food supplement based on hawthorn, lavender and hops extracts that induce sleep and relaxation.
2019 January - Italfarmaco strengthen its presence in rare disease area by launching the medicinal product VOTUBIA.
February - Italfarmaco launches NUPERAL in Italy, the first drug as fixed combination of doxilamine succinate and pyridoxine hydrochloride authorized for the symptomatic treatment of nausea and vomiting during pregnancy.